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Interaction between the BAG1S isoform
and HSP70 mediates the stability of anti-
apoptotic proteins and the survival of
osteosarcoma cells expressing oncogenic
MYC
Victoria J. Gennaro, Helen Wedegaertner and Steven B. McMahon*
Abstract
Background: The oncoprotein MYC has the dual capacity to drive cell cycle progression or induce apoptosis, depending
on the cellular context. BAG1 was previously identified as a transcriptional target of MYC that functions as a critical
determinant of this cell fate decision. The BAG1 protein is expressed as multiple isoforms, each having an array of distinct
biochemical functions; however, the specific effector function of BAG1 that directs MYC-dependent cell survival has not
been defined.
Methods: In our studies the human osteosarcoma line U2OS expressing a conditional MYC-ER allele was used to induce
oncogenic levels of MYC. We interrogated MYC-driven survival processes by modifying BAG1 protein expression. The
function of the separate BAG1 isoforms was investigated by depleting cells of endogenous BAG1 and reintroducing the
distinct isoforms. Flow cytometry and immunoblot assays were performed to analyze the effect of specific BAG1 isoforms
on MYC-dependent apoptosis. These experiments were repeated to determine the role of the HSP70 chaperone complex
in BAG1 survival processes. Finally, a proteomic approach was used to identify a set of specific pro-survival proteins
controlled by the HSP70/BAG1 complex.
Results: Loss of BAG1 resulted in robust MYC-induced apoptosis. Expression of the larger isoforms of BAG1, BAG1L and
BAG1M, were insufficient to rescue survival in cells with oncogenic levels of MYC. Alternatively, reintroduction of BAG1S
significantly reduced the level of apoptosis. Manipulation of the BAG1S interaction with HSP70 revealed that BAG1S
provides its pro-survival function by serving as a cofactor for the HSP70 chaperone complex. Via a proteomic approach
we identified and classified a set of pro-survival proteins controlled by this HSP70/BAG1 chaperone complex that
contribute to the BAG1 anti-apoptotic phenotype.
Conclusions: The small isoform of BAG1, BAG1S, in cooperation with the HSP70 chaperone complex, selectively
mediates cell survival in MYC overexpressing tumor cells. We identified a set of specific pro-survival clients controlled by
the HSP70/BAG1S chaperone complex. These clients define new nodes that could be therapeutically targeted to disrupt
the survival of tumor cells driven by MYC activation. With MYC overexpression occurring in most human cancers, this
introduces new strategies for cancer treatment.
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Background
The MYC oncogene encodes a transcription factor that
is a central driver of cell-cycle progression in both nor-
mal settings and in cancer [1, 2]. An enduring paradox
in the field is that MYC can also induce robust pro-
grammed cell death in some contexts [3]. As elevated
MYC is a universal hallmark of human cancer, a great
deal of effort has been expended in attempts to identify,
and ultimately manipulate, the molecular events that
convert the proliferative MYC program into an apoptotic
program [4]. We previously identified a transcriptional
target of MYC, termed BAG1, which is frequently over-
expressed in human cancer and predictive of poor prog-
nosis [5–8]. We formerly reported that blocking the
induction of BAG1 by MYC converted the cellular re-
sponse from proliferation to apoptosis [5].
The BAG1 gene encodes multiple protein isoforms
that have a variety of highly diverse functions [9–12].
For example, BAG1 functions as a molecular chaperone
responsible for proper protein folding and stability [13].
Additionally, BAG1 functions as a transcriptional cofac-
tor for nuclear steroid receptors [14–18]. What remains
unknown is which isoform-specific effector function of
BAG1 is responsible for its potent pro-survival activity
in the MYC pathway. The present study was undertaken
to identify this effector function and subsequently assess
the utility of targeting it to trigger the apoptosis of
tumor cells expressing elevated levels of MYC.
We report here that a single isoform of BAG1, termed
BAG1S, is responsible for the survival of tumor cells
with elevated MYC. The BAG1S isoform has been linked
to specific chaperone activities, in part through a phys-
ical association with the heat shock protein (HSP70).
Point mutations in BAG1S that selectively disrupt its
interaction with HSP70 eliminate the pro-survival func-
tion in MYC-expressing tumor cells. To gain an under-
standing of the specific biochemical events that
mediated this pro-survival function, a proteome-wide
screen was conducted that identified a unique set of
pro-survival effector proteins [19]. Of clinical relevance,
treatment of MYC-expressing tumor cells with a small
molecule HSP70 inhibitor phenocopies the loss of
BAG1S and selectively triggers the death of cells ex-
pressing oncogenic levels of MYC. Collectively, these
findings broaden our understanding of the biochemical
events that tumor cells trigger in order to survive in the
context of otherwise lethal forms of stress.
Methods
Cell culture and plasmid expression
The human cell line U2OS MYC-ER was generously
provided by Dr. Martin Eilers (University of Würzburg,
Würzburg, Germany). Cells were cultured in Dulbecco’s
modified Eagle’s medium (DMEM, Mediatech)
supplemented with 10% fetal calf serum (FBS, Gemini
Bio-Products) at 37 °C in 5% CO2.
BAG1L (50 kDa), BAG1M (46 kDa), and BAG1S (36
kDa) pcDNA3 expression plasmids were kindly provided
by Dr. Graham Packham (University of Southampton,
Southampton, UK). BAG1S C204A mutant was con-
structed by site-directed mutagenesis using QuikChange
(Agilent Technologies). The ectopic BAG1 cell lines
were generated by co-transfection of BAG1 plasmids
and .25 fold of eGFP plasmid (Addgene). Transfection
was performed using Continuum™ reagents according to
the manufacturer’s protocol (Gemini Bio-Products).
Cells were sorted by the Core Flow Cytometry Facility
(Thomas Jefferson University, Philadelphia, PA) and
cultured normally.
Lentiviral infection and treatments
As indicated, cells were infected with lentiviral shRNA
plasmids corresponding to BAG1 (NM_004323.4-
1189s21c1) directed against the 3’UTR and control lucif-
erase shRNA (SHC007) that were obtained from the
TRC collection (Sigma-Aldrich). Lentiviral packaging
plasmids (pCMV-R8.2 and pCMV-VSV-G) were cotrans-
fected with shRNA vectors into 293 T cells (ATCC).
Viral supernatants were collected, filtered, and added
directly to target cells in the presence of 8 μg/ml poly-
brene (Sigma Aldrich). Cells were selected with with
8 μg/mL puromycin (Sigma-Aldrich) 24 h after infection.
The MYC-ER fusion protein was activated by adding
4-hydroxytamoxifen (4-OHT) (Sigma Aldrich) at a final
concentration of 100 nM for indicated times. The HSP70
inhibitor MKT-077 (Sigma-Aldrich) was used at a final
concentration of 10uM for 48 h.
Apoptosis assays
To quantify apoptotic cell death, cells were collected by
trypsinization and stained using the Annexin V
PE-7AAD apoptosis detection kit (BD Pharmingen).
Fluorescence was detected by flow cytometry CytoFlex
LX Flow Cytometer (Beckman Coulter). 10,000 total
events were collected and subsequently analyzed for the
percentage of Annexin V-PE positive cells.
Quantitative RT-PCR
Quantitative RT-PCR (RT-PCR) was performed by
real-time analysis using the Step One Plus detection
system (Applied Biosystems) and FAST SYBR GREEN
PCR Master Mix kit (Applied Biosystems). RNA was
isolated and purified using the Trizol extraction method
(Invitrogen). cDNA was then generated using the
High-Capacity cDNA Reverse Transcription Kit (Applied
Biosystems).
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Immunoblotting and co-IP
Cells were harvested and lysed in E1A whole cell lysate
buffer supplemented with protease inhibitor cocktail
(Sigma-Aldrich). Immunoblotting concentration in ly-
sates was determined using the bicinchoninic acid
(BCA) assay and analyzed by SDS-PAGE using anti-
bodies against BAG1 (generously provided by Dr. Gra-
ham Packham), HSP70 (Abcam, #ab2787), PARP (Cell
Signaling, #9532), CASPASE-3 (Cell Signaling, #9662),
RAF1 (R&D Systems, #MAB3585), XIAP (Cell Signaling,
#2042), GCR (Cell Signaling, #3660), SLC7A6 (Thermo-
Fisher, #PA5–30575), POLR1D (ThermoFisher, #PA5–
30575), ACTIN (Santa Cruz, #sc-47,778), GAPDH
(Abcam, #ab9485).
For protein-protein interaction studies, ∼750 μg of
whole cell lysates (WCL) was used for immunoprecipita-
tion (IP). BAG1 IPs were performed by incubating
lysates with 10 μL Anti-BAG1 antibody (Abcam,
#ab32109) or Rabbit IgG control (Abcam, #ab172730)
for 16 h at 4 °C and precipitates captured using protein
A/G beads (Santa Cruz).
Proteomics LC-MS/MS
Experiment was performed in triplicate and all samples
collectively subjected to proteomics analysis. Cells stably
expressing vector control, BAG1S, or BAG1ΔS were
infected with shRNA directed against BAG1 or luciferase
(Vector-shLUC, Vector-shBAG1. BAG1S-shBAG1,
BAG1ΔS-shBAG1). Five days post-infection, conditions
were treated 100 nM 4-OHT for 12 h. Cellular extracts
were standardized for protein quantity and run 0.5 cm
into a 10% TRIS-Glycine gel (Invitrogen Novex). The
sample lanes and a gel control were cut out and sub-
sequently digested with trypsin. The digests were ana-
lyzed by LC-MS/MS on a Q Exactive HF mass
spectrometer using an extended LC method. MS/MS
spectra generated from the LC-MS/MS runs were
searched using full tryptic specificity against the Uni-
Prot human database (www.uniprot.org; 10/01/2017)
using the MaxQuant 1.6.1.0 program. “Match between
runs” feature was used to help transfer identifications
across experiments to minimize missing values. Pro-
tein quantification was performed using unique+razor
peptides. Razor peptides are shared (non-unique) pep-
tides assigned to the protein group with the most
other peptides (Occam’s razor principle). False discov-
ery rates for protein, and peptide identifications were
set at 1%.
The output from MaxQuant identified 6225 total pro-
teins. Common contaminants (e.g. keratins) and proteins
identified by a single peptide (low-confidence identifica-
tions) were removed yielding 4915 remaining proteins.
The abundance of a protein in a sample can be deter-
mined from the intensity i.e. the sum of the peptide MS
intensities for the protein. To account for larger proteins
generating more peptides, the intensity values were ad-
justed by dividing with the number of theoretical pep-
tides for each protein (iBAQ intensity). In addition, the
intensity values are also normalized (LFQ Intensity) to
take into account the potential differences in sample
loading. Normalization is done using the MaxLFQ algo-
rithm [19]. The LFQ intensities were log2 transformed
and then used for quantitative comparison. Student’s
t-test (p-value) and fold change were calculated for
binary comparison.
Conditions Vector-shBAG1, BAG1S-shBAG1,
BAG1ΔS-shBAG1 were all divided by Vector-shLUC to
normalize fold-change assessments to endogenous
BAG1 levels. These standardized fold-change values
were annotated knockdown (KD), BAG1S (S), and
BAG1ΔS (ΔS) respectively. Proteins were sorted and hits
with a p-value≤0.05 across all conditions were retained
(309 proteins). To increase the stringency, proteins that
did not have a ≥ |1.5| fold-change in the KD condition
were discarded (153 proteins). Proteins were classified
based on biological process characterized by UniProt. To
visualize changes a heatmap was constructed using soft-
ware described in Nucleic Acids Research (Babicki et al.,
Nucleic Acids Re, 2016).
The fold-changes of proteins in KD were compared
with S and ΔS values to determine if reintroduction of
either plasmid generated a partial rescue. Partial rescue
was defined by an increase of ≥10% compared to KD.
Statistical analysis
Data collected from at least three independent experi-
ments are presented as mean ± standard deviation. Stat-
istical testing was performed using SPSS with differences
between two groups determined by a Student’s t-test.
Significance is denoted in the figures as: ***P < 0.005;
**P < 0.02; *P < 0.05.
Results
BAG1 protein required for blocking MYC-driven apoptosis
To study MYC influence in malignant transformation, a
system employing a conditional MYC-ER allele has been
used extensively to mimic oncogenic levels of MYC
function [20, 21]. Treatment with the estrogen analog
4-hydroxytamoxifen (4-OHT) activates this MYC-ER fu-
sion protein and allows for induction of MYC activity
(Additional file 1: Figure S1). Depending on the cellular
context, MYC-ER cells display a robust MYC-dependent
surge in either proliferation or apoptosis [22]. In human
osteosarcoma U2OS MYC-ER cells where BAG1 induc-
tion was blocked, activation of MYC resulted in substan-
tial apoptotic cell death [5]. As we reported previously,
depletion of BAG1 followed by MYC activation via treat-
ment with 4-OHT, resulted in a significant increase in
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Fig. 1 BAG1 protein sufficient to suppress MYC-driven apoptosis. a U2OS MYC-ER cells depleted of BAG1 via infection with an shRNA-
encoding lentivirus directed against the 3’UTR or a luciferase shRNA control. Five days post-infection cells treated with ±100 nM 4-OHT for
48 h. Apoptosis measured by Annexin V-PE plus 7AAD DNA staining and quantified by FACS analysis. b Quantification of three experimental
replicates representing average and standard deviation of cumulative early and late apoptosis based on population of Annexin V-PE positive
cells. c PARP cleavage and BAG1 knockdown demonstrated by immunoblot (IB). F and C indicate full and cleaved species respectively.
d U2OS MYC-ER cells transfected with vectors encoding BAG1 or empty vector, followed by endogenous BAG1 depletion. IB demonstrating
efficient knockdown of endogenous BAG1 and retained ectopic BAG1 expression. e Cells from d cultured in ±100 nM 4-OHT for 48 h.
Apoptosis measured by Annexin V-PE plus 7AAD DNA staining and quantified by FACS analysis. f Quantification of three experimental
replicates representing average and standard deviation of apoptosis based on population of Annexin V-PE positive cells. g PARP cleavage
and BAG1 knockdown demonstrated by IB. F and C indicate full and cleaved species respectively. **p < 0.02
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apoptosis, as measured by either Annexin V staining or
immunblotting for PARP cleavage (Fig. 1a, b and c). To
verify that loss of BAG1 is the direct cause of the cell
death observed with this shRNA construct, U2OS
MYC-ER cells were generated to ectopically express the
three major isoforms of the BAG1 protein. This exogen-
ous BAG1 was resistant to knockdown by shRNA
directed against the 3’UTR, yielding a system where all
isoforms of endogenous BAG1 can be eliminated and
the cells then rescued with individual isoforms (Fig. 1d).
The combined ectopic expression of all three BAG1 iso-
forms significantly rescued the cell death marked by loss
of endogenous BAG1 as observed by flow cytometry and
apoptotic proteins to assess apoptosis (Fig. 1e, f and g).
This established a platform for further dissecting the
causal link between BAG1 and the suppression of
MYC-driven apoptosis.
The BAG1S isoform, but not BAG1L or BAG1M, is critical
for survival of cells expressing oncogenic levels of MYC
BAG1 protein exists as multiple isoforms which origin-
ate from a single transcript of the human BAG1 locus
on chromosome 9 [9, 10]. A selection of different trans-
lation start sites generate the major BAG1 isoforms:
BAG1L, BAG1M, and BAG1S [23]. The isoforms share a
common carboxyl terminus, which includes
ubiquitin-like and BAG domains [24]. However, the iso-
forms differ in the length of their amino termini. BAG1L
and BAG1M contain 10 hexapeptide motif (TRSEEX)
repeats, whereas BAG1S possess only four repeats. In
addition, the extended amino terminus of BAG1L holds
a nuclear localization signals (NLS) supporting its pre-
dominate localization to the nucleus [11]. Conversely,
BAG1M and BAG1S are mainly detected in the cytosol
[5, 9, 11, 23–25, 7–10] (Fig. 2a). Moreover, the different
isoforms of BAG1 are linked to different effector func-
tions. To assess the influence that different BAG1 iso-
forms have on MYC-dependent survival, U2OS MYC-ER
cells were generated to exogenously express the individ-
ual isoforms. Depletion of endogenous BAG1 in each
cell line demonstrated discrete rescue of either BAG1L,
M, or S isoform expression when compared to cells
transfected with vector control (Fig. 2b). As expected,
apoptosis assays (both Annexin V staining and immuno-
blotting for and PARP cleavage) using the control cells
demonstrated a substantial increase in cell death under
conditions of MYC activation and endogenous BAG1
depletion. Neither of the larger isoforms, BAG1L or
BAG1M, were sufficient to rescue survival in cells with
oncogenic levels of MYC. However, under these condi-
tions reintroduction of BAG1S significantly reduced the
level of apoptosis (Fig. 2c, d and e). The selective ability
of BAG1S in MYC-induced cells to repress death
strongly suggested that the small isoform of BAG1 plays
the key role in pro-survival function of BAG1 in this
context.
Interaction of BAG1S and HSP70 is essential for
regulating the survival of cells with oncogenic MYC
activity
Molecular chaperones of the 70kDA HSP70 family are
involved in a multitude of cellular processes, including
protein folding, protein translocation, and protein deg-
radation [26–28]. To mediate these diverse functions,
HSP70 cooperates with a variety of chaperone cofactors
[29]. Specific cofactors either modulate the ATPase and
peptide binding cycle of the chaperone or help direct
HSP70 to specific proteins and subcellular compart-
ments [30–32]. BAG1 is a component of the chaperone
system that binds to the ATPase domain of HSP70 [33].
By making use of the ATP-binding domain rather than
the substrate-binding domain, various other proteins can
attach to the chaperone complex [15, 32, 34–36]. Previ-
ous studies indicated that HSP70 interacts with each of
the BAG1 isoforms via the evolutionarily conserved
BAG domain located in the carboxyl terminus and that
these interactions enable different biochemical and
biological activities of target proteins [37, 38].
The HSP70 chaperone functions in part to eliminate
mis-folded or mis-targeted proteins [39, 40]. Removal of
corrupted proteins is crucial for cell viability because
these proteins accumulate as non-specific aggregates
which can become toxic to the cell [41, 42]. To deter-
mine if the anti-apoptotic function of BAG1S required
the HSP70 chaperone complex, a mutant BAG1S was
generated that prevented binding to HSP70 via a previ-
ously reported single amino acid change from a cysteine
(Cys) to alanine (Ala) at residue 204 (C204A) (Fig. 3a)
[43]. Stable U2OS MYC-ER cells expressing shRNA-re-
sistant BAG1S mutant (BAG1ΔS), BAG1S, and vector
control were developed and expression verified by
depleting the cells of endogenous BAG1 (Fig. 3b). Im-
munoprecipitation (IP) of BAG1 confirmed that BAG1S,
but not BAG1ΔS, was able to bind HSP70 (Add-
itional file 2: Figure S2).
Apoptosis assays (both Annexin V staining and im-
munoblotting for PARP cleavage) demonstrated that the
MYC-dependent cell death observed with loss of BAG1
is rescued by reintroduction of BAG1S but not BAG1ΔS
(Fig. 3d, e and f). These findings suggest that BAG1S
provides its pro-survival function by serving as a cofac-
tor for the HSP70 chaperone complex.
Furthermore, obstructing chaperone function with the
small molecule HSP70 inhibitor MKT-077 in
combination with MYC activation resulted in robust cell
death (Fig. 3g). Collectively, these data suggest that sup-
pressing HSP70/BAG1 chaperone function by repressing
expression/activity of either member separately or
Gennaro et al. BMC Cancer          (2019) 19:258 Page 5 of 14
Fig. 2 (See legend on next page.)
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disrupting the interaction, rescues MYC-driven apop-
tosis. Stated more directly, MYC activation triggers the
cell to become dependent on the cooperation and func-
tion of the HSP70/BAG1S chaperone complex for
survival.
Identification of a discreet set of pro-survival proteins
regulated by the HSP70/BAG1 complex
BAG1 can modulate the ATP-driven activity of HSP70
and this regulation of chaperone function may provide a
common mechanism to explain the diverse effects of
BAG1 [44]. Although the protein refolding activity of
HSP70 has received the greatest attention, chaperones
can participate in a multitude of processes including
protein translocation, stabilization, and degradation [26,
34]. BAG1 isoforms contain a ubiquitin-like domain
(Fig. 2a) and can directly bind components of the ubi-
quitylation machinery and regulate client protein stabil-
ity [12, 45, 46]. Glucocorticoid Receptor (GCR),
X-linked Inhibitor of Apoptosis Protein (XIAP), and
Rapidly Accelerating Fibrosarcoma 1 (RAF1) have been
previously described as clients of HSP70 chaperone ac-
tivity that function in part to activate pro-survival path-
ways [13, 43, 47]. To assess the dependence of MYC and
BAG1S on these established HSP70 client proteins, we
activated MYC for 12 or 24 h (as indicated) in context of
endogenous BAG1, loss of BAG1 or singularly expressed
BAG1S, both unmodified and mutated to prevent inter-
action with HSP70 (BAG1ΔS) (Fig. 4a). With 12 h of
oncogenic MYC activity, chaperone targets were not
substantially affected. However, after 24 h of MYC in-
duction, client proteins were stabilized in conditions
where the HSP70/BAG1S chaperone complex remained
intact (Fig. 4a). Importantly, the stabilization of
pro-survival proteins GCR, XIAP, and RAF1 by sus-
tained HSP70/BAG1S expression provides a potential
mechanisms by which BAG1S-dependent survival can
be controlled.
In an effort to evaluate proteins that could contribute to
BAG1S-driven pro-survival with early oncogenic MYC acti-
vation, an unbiased, comprehensive proteomics screen was
performed (Fig. 4c). Three experimental replicates were
subject to LC-MS/MS analysis to identify consistent and
significant protein alterations. A visual representation of the
proteomic analysis scheme is provided in Fig. 4b, and the
procedure is further described in the Methods. In brief,
levels of individual proteins from conditions with loss of
BAG1 (KD), ectopic BAG1S (S), and ectopic BAG1ΔS (ΔS)
were compared to levels in cells expressing endogenous
BAG1 (shLUC control). This allowed normalization of pro-
tein fold-changes. Proteins that had a significant p-value
(≤0.05) across all conditions and a change in expression of
≥|1.5| in knockdown (KD) were further assessed. The out-
put proteins were classified based on biological process
characterized by UniProt and differential expression of pro-
teins in each condition was visualized via heatmap (Fig. 4d).
Of the 153 proteins that whose levels were controlled by
BAG1, 56 were at least partially rescued by reintroduction
of BAG1S, and 30 of those were specific to BAG1S and not
HSP70-interaction deficient mutant BAG1ΔS (Fig. 4e). Sev-
eral of the proteins rescued by BAG1S and not BAG1ΔS
are presented in Table 1. Empirically assessing protein ex-
pression for two of the BAG1S-specific rescued proteins,
Solute Carrier Family 7 Member 6 (SLC7A6) and RNA
Polymerases I Subunit D (POLR1D), verified the results of
the screen (Fig. 4g). Of the 30 proteins whose regulation by
BAG1S correlates with protection from MYC-induced
apoptosis, nearly half have been previously associated with
survival [48–62]. Furthermore, the majority of identified
proteins were formerly linked with MYC (Table 1) [52, 58,
63–70]. BAG1 expression is a biomarker of poor prognosis,
presumably because it activates a pro-survival pathway that
tumor cells need in order to proliferate. By characterizing
additional members of this pro-survival process we are
closer to identifying methods to restore MYC-driven apop-
tosis. Importantly, several of the proteins identified are can-
didates for therapeutic targeting based on existing drugs
[71–74]. Collectively, this adds to the existing knowledge of
BAG1-mediated activity, which is summed and graphically
represented in Fig. 5.
Discussion
MYC is overexpressed in human cancer at an unparal-
leled frequency [4]. This is consistent with the ability of
(See figure on previous page.)
Fig. 2 Individual expression of BAG1 isoforms revealed BAG1S critical to inhibit MYC-dependent cell death. a Schematic detailing the structure of human
BAG1 isoforms L, M, and S. Amino acid positions shown on the top. Apparent molecular weights in kDa of protein products listed on the right. All isoforms
share a ubiquitin-like domain, BAG domain, and complete (BAG1L and M) or partial (BAG1S) TESEEX hexapeptide repeats. Nuclear localization signal (NLS)
domain present in BAG1L and partially in BAG1M. b U2OS MYC-ER cells transfected with vectors encoding distinct BAG1 isoforms L, M, S and an empty
vector control. Cells depleted of endogenous BAG1 via infection with an shRNA-encoding lentivirus directed against the 3’UTR. IB demonstrating individual
BAG1 isoform expression. c U2OS MYC-ER cells expressing distinct BAG1 isoforms depleted of endogenous BAG1 and treated with ±100 nM 4-OHT for
48 h. Apoptosis measured by Annexin V-PE plus 7AAD DNA staining and quantified by FACS analysis. d Quantification of three experimental replicates
representing average and standard deviation of cumulative early and late apoptosis based on population of Annexin V-PE positive cells. e PARP cleavage
and BAG1 expression demonstrated by IB from the same experiment but run on two separate gels. F and C indicate full and cleaved species
respectively. *p < 0.05
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Fig. 3 BAG1S mediated cell survival dependent on interaction with HSP70 chaperone. a Schematic demonstrating BAG1S interaction with
HSP70 chaperone (top) and a mutant BAG1ΔS that retains BAG1S structure but prevents HSP70 binding via a single amino acid change in
the BAG domain (bottom). b U2OS MYC-ER cells transfected with vectors encoding BAG1S, BAG1ΔS or empty vector, followed by
endogenous BAG1 depletion or shLUC control. IB demonstrating efficient knockdown of endogenous BAG1 and retained ectopic BAG1S
and BAG1ΔS expression. c U2OS MYC-ER cells expressing ectopic vector, BAG1S, or BAG1ΔS depleted of endogenous BAG1 via lentiviral
infection. Five days post-infection cells treated with ±100 nM 4-OHT for 48 h. Apoptosis measured by Annexin V-PE plus 7AAD DNA staining
and quantified by FACS analysis. d Quantification of three experimental replicates representing average and standard deviation of
cumulative early and late apoptosis based on population of Annexin V-PE positive cells. e PARP cleavage and BAG1 knockdown
demonstrated by IB. F and C indicate full and cleaved species respectively. f U2OS MYC-ER cells cultured with ±100 nM 4-OHT and 10uM
MKT-077 HSP70 inhibitor for 48 h. CAS-3 demonstrated by IB. F and C indicate full and cleaved species respectively. g Model detailing three
experimental methods used to interrupt HSP70/BAG1S chaperone complex activity. Limiting HSP70/BAG1S function via silencing BAG1,
inhibiting HSP70, and preventing BAG1S binding HSP70 all resulted in increased MYC-dependent death
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Fig. 4 Proteomic analysis identified proteins upregulated in the presence of pro-survival HSP70/BAG1S complex. a U2OS MYC-ER cells expressing
ectopic vector, BAG1S, or BAG1ΔS depleted of endogenous BAG1 protein. MYC activity induced for 12 or 24 h with ±100 nM 4-OHT treatment.
Lysates analyzed via IB to detect changes in known HSP70 chaperone client proteins GCR, XIAP and RAF1. b Schematic of experimental
conditions representing endogenous BAG1 (vector - shLUC), BAG1 knockdown (vector - shBAG1), BAG1S only (BAG1S - shBAG1), or BAG1ΔS only
(BAG1ΔS - shBAG1) evaluated for differences in global protein levels. Proteomics analysis outlined with exclusion criteria for significant protein
differences between samples. c Efficient knockdown of endogenous BAG1 and rescue of BAG1S and BAG1ΔS shown by IB for samples subjected
to proteomics analysis. d Proteomic hits assessed based on schematic of compiled proteins with ≥|1.5| fold change in knockdown compared to
control and p ≤ 0.05 across all conditions. Protein expression levels obtained for each sample indexed by specific protein and clustered by
UniProt biological process classification. P-values representative of experimental triplicates submitted for proteomic assessment. e Venn diagram
showing proteins partially rescued with reintroduction of BAG1S or BAG1ΔS. Increase of ≥10% constitutes a partial rescue. Overlapping proteins
with BAG1S or BAG1ΔS indicative of proteins rescued by either ectopic protein. f Verification of proteomics via detection of BAG1S rescued
targets SLC7A6 and POLR1D by IB.
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MYC to drive cell cycle progression, a phenotypic
hallmark of cancer [1, 2]. Ironically, MYC can also drive
apoptotic death, in some cellular context [75]. The ability
to rationally reprogram MYC function in tumors, from
cell cycle progression to apoptosis, could provide an at-
tractive therapeutic strategy. Among the biochemical
mechanisms that control the switch between cell cycle
and apoptosis is MYC’s ability to directly activate tran-
scription of the pro-survival gene BAG1 [5]. BAG1 is
often overexpressed in human cancer and elevated BAG1
levels is associated with poor prognosis [6–8].
While identification of BAG1’s role in this process was
a conceptual advance, BAG1’s functions are exceedingly
broad, thus presenting a barrier to identification of spe-
cific nodes for targeting. Adding to the complexity, the
BAG1 protein is expressed as several distinct isoforms
that have disparate activities and subcellular localizations
[9, 16, 23–25, 76]. As examples, BAG1L impacts gene
regulation by altering the activity of key nuclear hor-
mone receptor (NHR) transcription factors, including
the androgen receptor (AR), vitamin D receptor (VDR),
Activator Protein 1 (AP-1), and Estrogen Receptor (ER)
[18, 77–82]. Similarly, BAG1M cooperates with tran-
scription factors like AP-1 and cAMP Response
Element-Binding Protein (CREB) to mediate target gene
regulation [17, 18, 36].
Alternatively, BAG1M and BAG1S interact with HSP70
and regulate an array of molecular targets within the cyto-
plasm [45]. The different amino-termini of the distinct cyto-
plasmic BAG1 isoforms dictate the consequences of the
HSP70-mediated folding events of accessory proteins [9].
BAG1M inhibits the HSP70-mediated refolding of the
non-native polypeptide substrates, while BAG1S stimulates
HSP70 chaperone activity [45]. The antagonistic influence of
BAG1M and BAG1S on HSP70 regulation of client proteins
impacts different pathways involved in cell proliferation,
apoptosis, and stress response.
We demonstrate here that it is specifically the S isoform
of BAG1 that provides the survival function in MYC over-
expressing tumor cells. Using both genetic and pharmaco-
logical approaches, we further demonstrate that it is the
HSP70/BAGS1 chaperone complex that provides the sur-
vival function. Via a proteomic approach we identify and
then validate a set of specific proteins and pathways con-
trolled by this HSP70/BAG1S chaperone complex. Many
of the proteins identified are positively correlated with
MYC and have reported roles in survival pathways. The
identification and further characterization of these clients
Table 1 Classification of HSP70/BAG1S Clients
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of the HSP70/BAG1 complex provides the initial step to-
wards targeted therapies that can convert MYC from a
pro-tumorigenic oncogene to a pro-apoptotic tumor
suppressor.
Conclusion
The small isoform of BAG1, BAG1S, in cooperation
with the HSP70 chaperone complex, promotes cell
survival in MYC overexpressing tumor cells. We iden-
tify specific proteins controlled by the HSP70/BAG1S
chaperone complex that contribute to MYC-driven
pro-survival in cancer cells. The identification of
these HSP70/BAG1 chaperone clients introduces new
targets that could be therapeutically exploited to dis-
rupt the survival of tumor cells driven by MYC
activation.
Fig. 5 Proposed model of MYC-mediated BAG1 regulation and distinct functions of BAG1 isoforms. MYC activates gene transcription of BAG1
which produces BAG1 mRNA with three translation start sites that encode distinct protein isoforms BAG1L, M, and S. Nuclear BAG1L and BAG1M
cooperate with transcription factors to regulate gene expression. Cytoplasmic BAG1M and BAG1S interact with HSP70 to modulate chaperone
activity. As reported here, HSP70/BAG1S complex upregulates an array of proteins and inhibits MYC-driven apoptosis
Gennaro et al. BMC Cancer          (2019) 19:258 Page 11 of 14
Additional files
Additional file 1: Figure S1. MYC-ER simulates oncogenic MYC activity
in U2OS cancer cells. Activation of MYC-ER in U2OS cells with 4-OHT
treatment demonstrated characteristic loss of endogenous MYC expres-
sion and simultaneous mRNA induction of known MYC targets BAG1,
CAD and CCND2. (PDF 75 kb)
Additional file 2: Figure S2. Verification of HSP70 interaction with BAG1S
and not BAG1ΔS. Immunoprecipitation of BAG1 in U2OS MYC-ER cells with
depleted endogenous BAG1 and sustained ectopic expression of either
BAG1S or BAG1ΔS demonstrated HSP70 interaction with BAG1S, but not
BAG1ΔS. (PDF 375 kb)
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